Prof. Paul Ellis, Consultant Medical Oncologist

Prof. Paul Ellis

Consultant Medical Oncologist

Book online
|

Prof. Paul Ellis MD FRACP

Consultant Medical Oncologist

MD FRACP

Prof. Paul Ellis

Consultant Medical Oncologist MD FRACP

Book online
|
MD FRACP

Areas of expertise

  • Breast cancer treatments
  • Breast oncology
  • Lung cancer
  • Hepato-biliary cancer
  • Medical Oncology

Recommendations for Prof. Ellis

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byDr Bibi Maryam Ghalaie, GP

    Kind, caring and extremely generous with his time. A world expert in this field.

  • byDr Philippa Ruth Kaye, GP

    For medical oncology

  • byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon

    Prof. Paul Ellis is an experienced medical oncologist with a specialist interest in novel therapies for breast cancer management. As part of the multi-disciplinary team at the London Breast Institute, he provides patients with access to contemporary treatments from the latest trials.

  • byMr Simon Marsh, Consultant Breast and General Surgeon

    He is an internationally-recognised expert in breast cancer oncology treatments.

  • byMr Ali Noorani, Consultant Orthopaedic & Trauma Surgeon, Shoulder, Elbow & Upper Limb

    Excellent clinician. Dr Paul Ellis is a highly recommended Clinical Oncologist.

  • byDr James Mackay, Consultant Clinical Genetic Oncologist

    Prof. Paul Ellis is a specialist in breast cancer treatment.

  • byDr Bibi Maryam Ghalaie, GP

    Kind, caring and extremely generous with his time. A world expert in this field.

  • byDr Philippa Ruth Kaye, GP

    For medical oncology

  • byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon

    Prof. Paul Ellis is an experienced medical oncologist with a specialist interest in novel therapies for breast cancer management. As part of the multi-disciplinary team at the London Breast Institute, he provides patients with access to contemporary treatments from the latest trials.

  • byMr Simon Marsh, Consultant Breast and General Surgeon

    He is an internationally-recognised expert in breast cancer oncology treatments.

  • byMr Ali Noorani, Consultant Orthopaedic & Trauma Surgeon, Shoulder, Elbow & Upper Limb

    Excellent clinician. Dr Paul Ellis is a highly recommended Clinical Oncologist.

  • byDr James Mackay, Consultant Clinical Genetic Oncologist

    Prof. Paul Ellis is a specialist in breast cancer treatment.

  • Address

    • LOC at Chelsea

      102 Sydney Street, Chelsea, London, SW3 6NJ

    • LOC - Leaders in Oncology Care

      95-97 Harley Street, London, W1G 6AF

    • Private Care at Guy's at London Bridge Hospital

      Great Maze Pond, London, SE1 9RT

    About Prof. Paul Ellis

    GMC number: 3628979

    Year qualified: 1986

    Place of primary qualification: University of Otago

    Areas of expertise

    • Breast cancer
    • Hepato-biliary cancer
    • Lung cancer
    • Medical Oncology

    Professional memberships

    Royal Australasian College of Physicians and Pathologists
    General Medical Council

    Articles by Prof. Paul Ellis

    Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (er) –negative, but with grade in those with er-positive early-stage breast cancer suitable for cytotoxic chemotherapy

    Can routine data be used to support cancer clinical trials? a historical baseline on which to build: retrospective linkage of data from the tact (cruk 01/001) breast cancer trial and the national cancer data repository

    Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series

    Pik3ca mutations associated with gene signature of low mtorc1 signaling and better outcomes in estrogen receptor-positive breast cancer

    Phosphorylation of akt pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

    Dissecting the heterogeneity of triple-negative breast cancer